{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:13:32Z","timestamp":1769235212348,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Union\u2014Next Generation EU\u2014NRRP M6C2\u2014Investment 2.1","award":["#PNC-E3-2022-23683269-PNC-HLS-TA"],"award-info":[{"award-number":["#PNC-E3-2022-23683269-PNC-HLS-TA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32752-x","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:14:00Z","timestamp":1767165240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel fully human IgG1 targeting folate receptor \u03b1 demonstrates antitumor efficacy driven by avidity rather than monovalent binding affinity"],"prefix":"10.1038","volume":"16","author":[{"given":"Elena","family":"Pinto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Tresoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Arlotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Luison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Frigerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Corsiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia N.","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Canevari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia","family":"Mezzanzanica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Figini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"3","key":"32752_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","volume":"33","author":"FZ Nawaz","year":"2022","unstructured":"Nawaz, F. Z. & Kipreos, E. T. Emerging roles for folate receptor FOLR1 in signaling and cancer. Trends Endocrinol. Metab. 33 (3), 159\u2013174 (2022).","journal-title":"Trends Endocrinol. Metab."},{"issue":"6","key":"32752_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","volume":"17","author":"M Scaranti","year":"2020","unstructured":"Scaranti, M., Cojocaru, E., Banerjee, S. & Banerji, U. Exploiting the folate receptor \u03b1 in oncology. Nat. Rev. Clin. Oncol. 17 (6), 349\u2013359 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"32","key":"32752_CR3","doi-asserted-by":"publisher","first-page":"52553","DOI":"10.18632\/oncotarget.9651","volume":"7","author":"A Cheung","year":"2016","unstructured":"Cheung, A., Bax, H. J., Josephs, D. H., Tutt, A. N. & Karagiannis, S. N. Targeting folate receptor alpha for cancer treatment. Oncotarget 7 (32), 52553\u201352574 (2016).","journal-title":"Oncotarget"},{"issue":"1","key":"32752_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13046-019-1123-1","volume":"38","author":"B Frigerio","year":"2019","unstructured":"Frigerio, B., Bizzoni, C., Jansen, G., Matherly, L. H. & Figini, M. Folate receptors and transporters: Biological role and diagnostic\/therapeutic targets in cancer and other diseases. J. Experimental Clin. Cancer Res. 38 (1), 125 (2019).","journal-title":"J. Experimental Clin. Cancer Res."},{"issue":"8","key":"32752_CR5","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3390\/cancers15082383","volume":"15","author":"MSC Ornella","year":"2023","unstructured":"Ornella, M. S. C. et al. Immunotherapy for peritoneal carcinomatosis: Challenges and prospective outcomes. Cancers 15 (8), 2383 (2023).","journal-title":"Cancers"},{"issue":"14","key":"32752_CR6","doi-asserted-by":"publisher","first-page":"11288","DOI":"10.3390\/ijms241411288","volume":"24","author":"M Baydoun","year":"2023","unstructured":"Baydoun, M. et al. Folate receptor targeted photodynamic therapy: A novel way to stimulate Anti-Tumor immune response in intraperitoneal ovarian cancer. Int. J. Mol. Sci. 24 (14), 11288 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"32752_CR7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3389\/fimmu.2019.01994","volume":"10","author":"J Qi","year":"2019","unstructured":"Qi, J., Hymel, D., G Nelson, C., R Burke, T. & Rader, C. Conventional and chemically programmed asymmetric bispecific antibodies targeting folate receptor 1. Front. Immunol. 10, 1994 (2019).","journal-title":"Front. Immunol."},{"issue":"1","key":"32752_CR8","doi-asserted-by":"publisher","first-page":"100917","DOI":"10.1016\/j.currproblcancer.2022.100917","volume":"47","author":"O Young","year":"2023","unstructured":"Young, O. et al. Folate receptor as a biomarker and therapeutic target in solid tumors. Curr. Probl. Cancer. 47 (1), 100917 (2023).","journal-title":"Curr. Probl. Cancer"},{"key":"32752_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.lungcan.2020.05.002","volume":"145","author":"N Tamura","year":"2020","unstructured":"Tamura, N. et al. Correlation between the expression of folate receptor alpha (FR\u03b1) and clinicopathological features in patients with lung adenocarcinoma. Lung Cancer. 145, 152\u2013157 (2020).","journal-title":"Lung Cancer"},{"issue":"9","key":"32752_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/1061186X.2023.2245579","volume":"31","author":"L Kumari","year":"2023","unstructured":"Kumari, L. et al. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer. J. Drug Target. 31 (9), 889\u2013907 (2023).","journal-title":"J. Drug Target."},{"key":"32752_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/OTT.S351500","volume":"15","author":"J Schnoell","year":"2022","unstructured":"Schnoell, J. et al. Protein expression of folate receptor alpha in adenoid cystic carcinoma of the head and neck. Onco Targets Ther. 15, 531\u2013538 (2022).","journal-title":"Onco Targets Ther."},{"issue":"1","key":"32752_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","volume":"130","author":"E Despierre","year":"2013","unstructured":"Despierre, E. et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol. Oncol. 130 (1), 192\u2013199 (2013).","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"32752_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13402-011-0052-6","volume":"35","author":"LMA Crane","year":"2012","unstructured":"Crane, L. M. A. et al. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell. Oncol. (Dordr). 35 (1), 9\u201318 (2012).","journal-title":"Cell. Oncol. (Dordr)"},{"issue":"3","key":"32752_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ijc.2910390306","volume":"39","author":"S Miotti","year":"1987","unstructured":"Miotti, S. et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer. 39 (3), 297\u2013303 (1987).","journal-title":"Int. J. Cancer"},{"issue":"4","key":"32752_CR15","first-page":"301","volume":"5","author":"B Frigerio","year":"2022","unstructured":"Frigerio, B., Montermini, M., Canevari, S. & Figini, M. Role of antibody engineering in generation of derivatives starting from MOv19 mab: 40 years of biological\/therapeutic tools against folate receptor Alfa. Antib. Ther. 5 (4), 301\u2013310 (2022).","journal-title":"Antib. Ther."},{"issue":"13","key":"32752_CR16","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis, U. A. et al. Efficacy and safety of Mirvetuximab Soravtansine in patients with Platinum-Resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J. Clin. Oncol. 41 (13), 2436\u20132445 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"32752_CR17","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore, K. N. et al. Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant ovarian cancer. N Engl. J. Med. 389 (23), 2162\u20132174 (2023).","journal-title":"N Engl. J. Med."},{"issue":"19","key":"32752_CR18","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","volume":"29","author":"A Dilawari","year":"2023","unstructured":"Dilawari, A. et al. FDA approval summary: Mirvetuximab Soravtansine-Gynx for FR\u03b1-Positive, Platinum-Resistant ovarian cancer. Clin. Cancer Res. 29 (19), 3835\u20133840 (2023).","journal-title":"Clin. Cancer Res."},{"key":"32752_CR19","doi-asserted-by":"crossref","unstructured":"Shah, P. et al. 431 First-in-human phase I clinical trial evaluating intraperitoneal administration of MOv19-BBz CAR T cells in patients with alpha folate receptor-expressing recurrent high grade serous ovarian cancer. J. Immunother. Cancer 9(Suppl 3): A461\u2013A461. https:\/\/jitc.bmj.com\/content\/9\/Suppl_2\/A461 (2021).","DOI":"10.1136\/jitc-2021-SITC2021.431"},{"key":"32752_CR20","first-page":"899","volume":"9","author":"LS Jespers","year":"1994","unstructured":"Jespers, L. S., Roberts, A., Mahler, S. M., Winter, G. & Hoogenboom, H. R. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnol. (N Y). 9, 899\u2013903 (1994).","journal-title":"Biotechnol. (N Y)"},{"issue":"5","key":"32752_CR21","first-page":"991","volume":"58","author":"M Figini","year":"1998","unstructured":"Figini, M. et al. Panning phage antibody libraries on cells: isolation of human fab fragments against ovarian carcinoma using guided selection. Cancer Res. 58 (5), 991\u2013996 (1998).","journal-title":"Cancer Res."},{"issue":"4","key":"32752_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00262-008-0575-5","volume":"58","author":"M Figini","year":"2009","unstructured":"Figini, M. et al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol. Immunother. 58 (4), 531\u2013546 (2009).","journal-title":"Cancer Immunol. Immunother"},{"issue":"12","key":"32752_CR23","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2967\/jnumed.110.086819","volume":"52","author":"A Zacchetti","year":"2011","unstructured":"Zacchetti, A. et al. Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer. J. Nucl. Med. 52 (12), 1938\u20131946 (2011).","journal-title":"J. Nucl. Med."},{"key":"32752_CR24","first-page":"2448","volume":"54","author":"L Coney","year":"1994","unstructured":"Coney, L. et al. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res. 54, 2448\u20132455 (1994).","journal-title":"Cancer Res."},{"issue":"1","key":"32752_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/jcb.240580107","volume":"58","author":"P Casalini","year":"1995","unstructured":"Casalini, P. et al. Unidirectional potentiation of binding between two anti-FBP mabs: evaluation of the involved mechanisms. J. Cell. Biochem. 58 (1), 47\u201355 (1995).","journal-title":"J. Cell. Biochem."},{"key":"32752_CR26","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.3389\/fimmu.2019.02514","volume":"10","author":"A Satta","year":"2019","unstructured":"Satta, A. et al. A bispecific antibody to link a TRAIL-Based antitumor approach to immunotherapy. Front. Immunol. 10, 2514 (2019).","journal-title":"Front. Immunol."},{"issue":"2","key":"32752_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","volume":"128","author":"HJ Bax","year":"2023","unstructured":"Bax, H. J. et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br. J. Cancer. 128 (2), 342\u2013353 (2023).","journal-title":"Br. J. Cancer"},{"key":"32752_CR28","first-page":"6","volume":"7","author":"W Ebel","year":"2007","unstructured":"Ebel, W. et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 7, 6 (2007).","journal-title":"Cancer Immun."},{"key":"32752_CR29","doi-asserted-by":"crossref","unstructured":"Mazor, Y. et al. Enhancement of immune effector functions by modulating IgG\u2019s intrinsic affinity for target antigen. PLoS ONE, 11 (6), 1\u201320 (2016).","DOI":"10.1371\/journal.pone.0157788"},{"issue":"1","key":"32752_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang, R. et al. Antibody-Drug conjugates (ADCs): current and future biopharmaceuticals. J. Hematol. Oncol. 18 (1), 51 (2025).","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"32752_CR31","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1038\/s41598-022-11648-0","volume":"12","author":"R Evans","year":"2022","unstructured":"Evans, R. et al. Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting. Sci. Rep. 12 (1), 7677 (2022).","journal-title":"Sci. Rep."},{"issue":"6","key":"32752_CR32","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","volume":"71","author":"SI Rudnick","year":"2011","unstructured":"Rudnick, S. I. et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 71 (6), 2250\u20132259 (2011).","journal-title":"Cancer Res."},{"issue":"7","key":"32752_CR33","first-page":"1191","volume":"31","author":"K Fujimori","year":"1990","unstructured":"Fujimori, K., Covell, D. G., Fletcher, J. E. & Weinstein, J. N. A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier. J. Nucl. Med. 31 (7), 1191\u20131198 (1990).","journal-title":"J. Nucl. Med."},{"issue":"18","key":"32752_CR34","first-page":"4776","volume":"51","author":"W van Osdol","year":"1991","unstructured":"van Osdol, W., Fujimori, K. & Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a \u2018binding site barrier\u2019. Cancer Res. 51 (18), 4776\u20134784 (1991).","journal-title":"Cancer Res."},{"issue":"15","key":"32752_CR35","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1158\/0008-5472.CAN-20-3822","volume":"81","author":"BM Bordeau","year":"2021","unstructured":"Bordeau, B. M., Yang, Y. & Balthasar, J. P. Transient competitive Inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy. Cancer Res. 81 (15), 4145\u20134154 (2021).","journal-title":"Cancer Res."},{"issue":"12","key":"32752_CR36","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00262-005-0693-2","volume":"54","author":"A Coliva","year":"2005","unstructured":"Coliva, A. et al. 90Y labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol. Immunother. 54 (12), 1200\u20131213 (2005).","journal-title":"Cancer Immunol. Immunother"},{"key":"32752_CR37","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1038\/srep05885","volume":"4","author":"TS Dodev","year":"2014","unstructured":"Dodev, T. S. et al. A tool kit for rapid cloning and expression of Recombinant antibodies. Sci. Rep. 4, 5885 (2014).","journal-title":"Sci. Rep."},{"issue":"9","key":"32752_CR38","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/j.ejca.2013.01.024","volume":"49","author":"B Frigerio","year":"2013","unstructured":"Frigerio, B. et al. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur. J. Cancer. 49 (9), 2223\u20132232 (2013).","journal-title":"Eur. J. Cancer"},{"key":"32752_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-0716-2376-3_10","volume":"2508","author":"MS Tabatabaei","year":"2022","unstructured":"Tabatabaei, M. S. & Ahmed, M. Enzyme-Linked immunosorbent assay (ELISA). Methods Mol. Biol. 2508, 115\u2013134 (2022).","journal-title":"Methods Mol. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32752-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32752-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32752-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:04:11Z","timestamp":1769216651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32752-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32752"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32752-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"I confirm that the use of the patients ascitic fluid cells has been approved by the ethical committee CET Lombardia 4; identificative number INT131\/23.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Ascitic fluid samples, collected during routine medical procedures, were made available for research purposes, in accordance with the institutional guidelines. Clinical details were recorded, and samples were assigned with a reference number to retain anonymity.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"2956"}}